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Allogeneic unrelated hematopoietic stem cell transplants
(HSCT) are complex procedures that need adequate hospital
infrastructure, a competent team, high-cost procedures and
medications. Most transplants that are performed in Brazil
are paid by the government. The national health system
reimburses the hospital U$ 35,801.00 as a ﬂat rate. The
government has recently increased this amount by 60% but
there are not national studies to use to evaluate the appro-
priateness of this amount. The objective of this study was to
retrospectively evaluate the cost of ten consecutive unrelated
donor HSCT performed in our institution.
Methods: Theprojectwas approved byour IRB (CEP-UNIFESP
#1875/11) and granted waiver to request consent. The costs
wereevaluated fromtheﬁrst appointmentuntil oneyear after
transplant or death divided as 1) pre-HSCT, 2) conditioning
therapy, 3) from the day of transplant until ﬁrst discharge, 4)
until D+100, 5) until D+180, and 6) until D+360. The costs
included medications, supplies, blood transfusions, labora-
tory, imaging and the cost of the ward. Housing and out-of
pocket costs or loss of income were not evaluated. Patients
were scored 1 to 3 according to the Pediatric EBMT score.
Results: Ten consecutive children 2-14 years of age under-
went unrelated donor HSCT from June, 2010 to May, 2011.
Diagnoses were ALL (4). AML (3), lymphoma (2), and aplastic
anemia (1). Three patients had early disease and others were
in advanced phases of the disease. Eight were CMV positive.
Five hadmarrow and ﬁve cord blood transplants. Themedian
interval to transplant was 3.7 years from diagnosis and 80
days from referral. The patients remained hospitalized for
a median of 80 days (21-50). Median time to engraftment
was D+22 (12-56) and six had complications and needed
Intensive Care support. Of the 10 children, seven were dis-
charged but three eventually relapsed and died, overall
survival is 50%. The median total cost during the ﬁrst year
was U$118,908.00 (mean U$ 139,861.00) e 44% of that spent
within the ﬁrst 100 days post HSCT. The ﬁrst admission had
a median total cost of U$ 64,385.00 (14,400 e 166,792). Total
costs were approximately 40% higher than the direct cost.
The highest costs were blood products and medications. No
relationship was found between cost and age, gender, graft
source of Pediatric EBMT-score.
Conclusion: Unrelated-donor HSCT is an expensive proce-
dure and the government only partially reimburses its cost.
Even with a 60% increase in reimbursement there will be
a deﬁcit in more than half of the procedures. We are working
to increase the amount paid for speciﬁc complications and
will have to continue to ﬁnd alternative resources to pay for
the transplants.343
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Materials and Methods: We retrospectively reviewed 76
medical records of patients older than 50 years receiving an
allogeneic HSCT in our centers. We evaluated the following
characteristics: sex, age, diagnosis, stage, comorbidities
(according to the HCT-CI score), type of donor, histocom-
patibility, conditioning and immunosupression. We analyzed
the incidence and severity of Graft-vs-Host disease (GVHD)
and treatment related mortality (TRM) with Chi Square and
Overall Survival (OS) and Disease Free Survival (DFS) with
Kaplan Meier. For multivariate analysis (MA) we used Cox
regression model for time dependant outcomes and logistic
regression for dichotomic variables, considering signiﬁcant
a P < .05.
Results: Between March 1998 and June 2012, 76 transplants
were performed with a median follow up of 1.9 years.
Fourteen patients were older than 60 years, 51 were male,
HCT-CI score was 0 (41%), 1 (36%), 2 (23%), common diag-
nosis were AML (35%), MDS (30%) and MPN (20%), 65% were
in late stage, 80% received a transplant from a MRD, 37%
received FluMel conditioning regimen, 32% FluBu and 12%
BuCy, 66% received tacrolimus (Fk) based regimen and 34%
cyclosporine. Acute GVHD (aGVHD) incidencewas 51%, aGVH
grade II-IV 29%. AML patients had a lower incidence of
aGVHD (36% vs. 61%, P < .03) still signiﬁcant in MA (HR 0.27;
95% CI 0.07-0.98;P¼ .04) as well as FluMel conditioning (33%
vs. 59%,P¼ .02), in contrast to unrelated donor (URD) (aGVHD
GII-IV 53% vs. 23%,P¼ .02). Chronic GVHD incidence was 33%,
extensive in 10%. Early TRM (day 100) was 17% and global
30%. Female patients had lower early TRM (4% vs. 25%,P ¼
.02) opposite to HCT-CI score 2 patients that experienced
a higher global TRM (58% vs. 26%, P < .04) still signiﬁcant in
MA (HR 4.6; 95% CI 1.03-20.9;P¼ .04) as well as MPN patients
(64% vs. 25%, P < .01) also signiﬁcant in MA (HR 7.2; 95% CI
1.20-43.7;P ¼ .03). OS was 43% (1 year) and 20% (3 years).
Patients older than 60 had a higher OS (1/3 years 61/43% vs.
38/14%;P ¼ .01), while FluBu was associated to a lower OS (1/
3 years 25/10% vs. 49/23%, P < .05), not signiﬁcant in MA.
Regarding immunosuppressant, the use of Fk was associated
with a higher OS (1/3 years 44/20% vs. 19/6%, P < .01)
signiﬁcant in MA (HR 0.45; 95% CI 0.2-0.9;P ¼ .04) and DFS
(1/3 years 33/18% vs. 11/5%,P ¼ .01).
Conclusion: According to the literature, URD is associated
with a higher incidence of clinical signiﬁcant aGVHD (P¼ .02)
and FluMel presented lower incidence of aGVHD as well as
AML patients. Regarding TRM female patients had a lower
early TRM and lower HCT-CI score had lower global TRM.
FluBu was associated with a lower OS, while Fk patients had
a higher OS and DFS. Interestingly patients older than 60 had
higher OS not signiﬁcant in MA, probably due to a better
selection: none had HCT-CI higher than 1, only 1 patient
received an URD transplant, most of them received Fk base
immunosuppressant and all of them received a NMA trans-
plant.344
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Table 1
* Total
N 222
Age 58 (20-72)
HCT-SCI 0-1/2/>3 53/54/90
PS 90-100/70-80/50-60 107/108/7
AML/ALL/MDS/NHL and HD/MM/others 76/10/22/71/35/8
Disease Risk index
Low/Int/High/VHigh
26/132/58/6 12%/59%/26%/3%
MRD/MUD/ MMUD 111/77/34 50%/35%/15%
* HCT-SCI indicates: hematopoietic cell transplantation speciﬁc comor-
bidity index; MRD, Matched related donor; MUD, Matched unrelated donor;
MMUD, Mismatched unrelated donor
Table 2
n 2-y OS 2-y PFS 2-y RR 2-y NRM
All patients 222 64% 54% 28% 20%
Low DRI 26 (12% 92% 69% 8% 13%
Int DRI 132 (59%) 69% 56% 27% 21%
High/VHigh DRI 64 (29%) 43% 40% 38% 31%
> 58 years 120 61% 50% / 27%
< 58 years 102 67% 60% / 16%
MRD 111 67% 53% / 16%
MUD+ MMUD 111 60% 55% / 28%
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Innate and therapy-induced states of immunosuppres-
sion are associated with a variety of potentially infectious
idiopathic clinical syndromes. Using unbiased, next-genera-
tion sequencing, we investigated the metagenome of cord
colitis syndrome (CCS), a recently described transplantation-
associated colitis syndrome, in order to identify a candidate
infectious trigger. Shotgunwhole genome sequencing of DNA
was performed followed by computational classiﬁcation of
reads. A large proportion of reads remained unmapped,
suggesting the presence of a potentially novel organism. In
order to investigate the source of these unmapped reads, de
novo computational assembly of nonhuman reads was per-
formed and yielded 98 contigs of > 2.5kb in length covering
a total of 7.65Mb. Read coverage and GC content was similar
for all of these contigs, suggesting they corresponded to
a common organism. Phylogenetic analysis of this draft
genome revealed that this organism was a novel species,
which we have provisionally named Bradyrhizobium enterica.
PCR conﬁrmed the presence of B. enterica in three additional
CCS patients and demonstrated absence of B. enterica in
normal colon, colon cancer and graft-versus-host disease
controls. In summary, we have demonstrated the assembly of
a novel bacterial draft genome from human tissue specimens
without isolation or culture of the organism. This organism,
provisionally named B. enterica, is associated with CCS sug-
gesting that it may function as an opportunistic human
pathogen.345
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Introduction: We have treated 222 consecutive patients
eligible for allo HSCT with the same RIC from June 2005 up to
March 2012.We particularly studied the impact of age, donor
source and of the recent disease risk index (DRI) published
by Amand et al (Blood 2012).
Patients and methods: All patients were treated for
hematologic malignancies and were prepared with Flu-
darabin (30 mg/m2/D x 5 D, IV Busulfan (3.2 mg/Kg/D x 2
D, and rabbit antithymocyte globulin (rATG) (2.5 mg/Kg/D
x 2 D). All patients received CSA from D-1 with the
addition of MMF in case of MMUD as post graft
immunosuppression.Results: As for August 2012, follow-up is 24 months (4-77).
Patients characteristics are presented in Table 1; median age
was 58 years with 45% and 30% of the patients presenting
with a HCT-SCI > 2 and a high or very high DRI
respectively. 50% of donors were related siblings. Analyses
of outcomes are presented in Table 2. Age only inﬂuenced
NRM (P ¼ .21). Donor origin has no inﬂuence on any
outcome variable. DRI inﬂuenced OS (P ¼ .000017) (Figure
1), PFS (P ¼ .00045) (Figure 2), relapse (P ¼ .0073) and at
a lesser degree NRM (P ¼ .056).
Conclusions: Overall results are promising. They validate the
previously published DRI and indicate populations where
efforts should be focused. Interestingly results are similar
whatever the donor is.346
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Purpose: Over the years, we have tuned the chemotherapy
dose intensity of a busulfan based RIC regimen with the aim
to better control disease while retaining a low toxicity
proﬁle. Here, we retrospectively analyzed a cohort of patients
with myeloid malignancies treated identically in two French
centers.
Patients and methods: From 2005 to 2010 in Marseille and
Nantes we transplanted 165 patients (median age: 56.8 years
